On July 30, 2024 Tvardi Therapeutics, Inc. ("Tvardi"), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, reported that Imran Alibhai, PhD, Chief Executive Officer of Tvardi Therapeutics will participate in a fireside chat at the 2024 BTIG Virtual Biotechnology Conference on Tuesday, August 6, 2024, at 10:00 AM ET (Press release, Tvardi Therapeutics, JUL 31, 2024, View Source [SID1234645173]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In addition to the fireside chat, the management team will hold one-on-one investor meetings Monday and Tuesday, August 5-6, 2024. If you are interested in meeting with the Tvardi Therapeutics management team during the conference, please reach out to BTIG.